Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12216MR)

This product GTTS-WQ12216MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12216MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1428MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ10485MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ6612MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ6918MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ14547MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ2275MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ5053MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CaCP-29
GTTS-WQ7763MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW